LDL-C and Cardiovascular Disease Risk
Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.
Read More
Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.
Read More
Barriers and Solutions for Lipid Management in Clinical Practice
An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.
Read More
Multidisciplinary/Team Based Approach for Lipid Management
Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.
Read More
The Role of Combination Therapy in Hypercholesterolemia
Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.
Read More
Managing ASCVD in Patients With Statin Intolerance
A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.
Read More
Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores
Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.
Read More
Guideline Recommendations for Lipid Lowering
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.
Read More
Lipid Lowering Agents Beyond Statins: Bempedoic Acid
A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.
Read More
Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.
Read More
Use of Statins in Management of Hypercholesterolemia
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.
Read More
Personalized Treatment for Patients with ASCVD
Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.
Read More
Impact of Lipid Lowering on Risk for ASCVD
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.
Read More
Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.
Read More
Future Directions for the Treatment of ASCVD and Hypercholesterolemia
Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.
Read More
Emerging Agents for Treatment of Hypercholesterolemia and ASCVD
Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.
Read More
ASCVD and Hypercholesterolemia: Patient Selection for Bempedoic Acid
Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.
Read More
Safety and Efficacy of Bempedoic Acid for ASCVD and Hypercholesterolemia
Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.
Read More
ASCVD and Hypercholesterolemia: Combination Therapy and Statin Intolerance
Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.
Read More
Role of Icosapent Ethyl in Managing ASCVD and Other Lipid Disorders
Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.
Read More
Older Agents to Manage ASCVD and Hypercholesterolemia
Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.
Read More
Bempedoic Acid to Manage ASCVD and Hypercholesterolemia
Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.
Read More
Managing ASCVD and Hypercholesterolemia: Statins, Ezetimibe, and PCSK9 Inhibitors
Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.
Read More
Implementing Lifestyle Modifications for ASCVD and Hypercholesterolemia Management
Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.
Read More
DCRM Practice Recommendations for ASCVD and Metabolic Diseases
Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.
Read More